RecruitingPHASE1, PHASE2NCT04997317

Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide

Studying Meningioma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University Hospital, Basel, Switzerland
Principal Investigator
Dominik Cordier, PD Dr. med.
University Hospital, Basel, Switzerland
Intervention
177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over)(drug)
Enrollment
18 enrolled
Eligibility
18 years · All sexes
Timeline
20212026

Study locations (1)

Collaborators

Swiss Cancer League

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04997317 on ClinicalTrials.gov

Other trials for Meningioma

Additional recruiting or active studies for the same condition.

See all trials for Meningioma

← Back to all trials